Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Class A common stock, $0.0001 par value per share | CANO | The New York Stock Exchange | ||||||||||||
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share | CANO/WS | The New York Stock Exchange |
Page | |||||
PART I FINANCIAL INFORMATION | |||||
2 | |||||
PART II. OTHER INFORMATION | |||||
(in thousands, except share and per share data) | March 31, 2022 | December 31, 2021 | ||||||||||||
Assets | ||||||||||||||
Current assets: | ||||||||||||||
Cash, cash equivalents and restricted cash | $ | 113,052 | $ | 163,170 | ||||||||||
Accounts receivable, net of unpaid service provider costs | 191,724 | 133,433 | ||||||||||||
Prepaid expenses and other current assets | 18,859 | 20,632 | ||||||||||||
Total current assets | 323,635 | 317,235 | ||||||||||||
Property and equipment, net | 95,595 | 85,261 | ||||||||||||
Operating lease right-of-use assets | 152,180 | 132,173 | ||||||||||||
Goodwill | 772,704 | 769,667 | ||||||||||||
Payor relationships, net | 569,086 | 576,648 | ||||||||||||
Other intangibles, net | 241,963 | 248,973 | ||||||||||||
Other assets | 16,602 | 13,582 | ||||||||||||
Total assets | $ | 2,171,765 | $ | 2,143,539 | ||||||||||
Liabilities and stockholders' equity | ||||||||||||||
Current liabilities: | ||||||||||||||
Current portion of notes payable | $ | 6,444 | $ | 6,493 | ||||||||||
Current portion of finance lease liabilities | 1,448 | 1,295 | ||||||||||||
Current portion of contingent consideration | 3,062 | 3,123 | ||||||||||||
Accounts payable and accrued expenses | 93,368 | 80,829 | ||||||||||||
Current portions due to sellers | 1,480 | 17,357 | ||||||||||||
Current portion of operating lease liabilities | 18,383 | 15,275 | ||||||||||||
Other current liabilities | 34,472 | 36,664 | ||||||||||||
Total current liabilities | 158,657 | 161,036 | ||||||||||||
Notes payable, net of current portion and debt issuance costs | 915,738 | 915,266 | ||||||||||||
Long term portion of operating lease liabilities | 141,477 | 122,935 | ||||||||||||
Warrant liabilities | 52,982 | 80,144 | ||||||||||||
Long term portion of finance lease liabilities | 2,738 | 2,181 | ||||||||||||
Contingent consideration | 30,700 | 35,300 | ||||||||||||
Other liabilities | 31,696 | 28,109 | ||||||||||||
Total liabilities | 1,333,988 | 1,344,971 | ||||||||||||
Stockholders’ Equity | ||||||||||||||
Shares of Class A common stock $0.0001 par value (6,000,000,000 shares authorized and 205,026,367 and 180,113,551 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively) | 20 | 18 | ||||||||||||
Shares of Class B common stock $0.0001 par value (1,000,000,000 shares authorized and 276,722,704 and 297,385,981 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively) | 28 | 30 | ||||||||||||
Additional paid-in capital | 464,262 | 397,443 | ||||||||||||
Accumulated deficit | (78,100) | (78,760) | ||||||||||||
Total Stockholders' Equity before non-controlling interests | 386,210 | 318,731 | ||||||||||||
Non-controlling interests | 451,567 | 479,837 | ||||||||||||
Total Stockholders' Equity | 837,777 | 798,568 | ||||||||||||
Total Liabilities and Stockholders' Equity | $ | 2,171,765 | $ | 2,143,539 |
Three Months Ended March 31, | ||||||||||||||
(in thousands, except share and per share data) | 2022 | 2021 | ||||||||||||
Revenue: | ||||||||||||||
Capitated revenue (Related parties comprised $0 and $179,509 for the three months ended March 31, 2022 and 2021, respectively) | $ | 674,351 | $ | 261,357 | ||||||||||
Fee-for-service and other revenue (Related parties comprised $0 and $412 for the three months ended March 31, 2022 and 2021, respectively) | 29,986 | 13,245 | ||||||||||||
Total revenue | 704,337 | 274,602 | ||||||||||||
Operating expenses: | ||||||||||||||
Third-party medical costs (Related parties comprised $0 and $133,844 for the three months ended March 31, 2022 and 2021, respectively) | 535,779 | 195,046 | ||||||||||||
Direct patient expense (Related parties comprised $1,454 and $1,430 for the three months ended March 31, 2022 and 2021, respectively) | 60,677 | 34,237 | ||||||||||||
Selling, general, and administrative expenses (Related parties comprised $1,677 and $1,091 for the three months ended March 31, 2022 and 2021, respectively) | 96,587 | 35,009 | ||||||||||||
Depreciation and amortization expense | 19,036 | 5,846 | ||||||||||||
Transaction costs and other | 8,375 | 8,954 | ||||||||||||
Change in fair value of contingent consideration | (4,661) | 285 | ||||||||||||
Total operating expenses | 715,793 | 279,377 | ||||||||||||
Loss from operations | (11,456) | (4,775) | ||||||||||||
Other income and expense: | ||||||||||||||
Interest expense | (13,284) | (10,626) | ||||||||||||
Interest income | 1 | 1 | ||||||||||||
Loss on extinguishment of debt | (1,428) | — | ||||||||||||
Change in fair value of warrant liabilities | 27,162 | — | ||||||||||||
Total other income (expense) | 12,451 | (10,625) | ||||||||||||
Net income (loss) before income tax expense | 995 | (15,400) | ||||||||||||
Income tax expense | 1,080 | 714 | ||||||||||||
Net loss | $ | (85) | $ | (16,114) | ||||||||||
Net loss attributable to non-controlling interests | (745) | — | ||||||||||||
Net income attributable to Class A common stockholders | $ | 660 | $ | — | ||||||||||
Net income per share attributable to Class A common stockholders, basic | $ | 0.00 | N/A | |||||||||||
Net loss per share attributable to Class A common stockholders, diluted | $ | 0.00 | N/A | |||||||||||
Weighted-average shares outstanding: | ||||||||||||||
Basic | 191,410,221 | N/A | ||||||||||||
Diluted | 468,132,925 | N/A | ||||||||||||
(in thousands, except shares) | Members' Capital | Class A Shares | Class B Shares | Additional Paid-in Capital | Notes Receivable | Accumulated Deficit | Non-Controlling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2021 | — | $ | — | 180,113,551 | $ | 18 | 297,385,981 | $ | 30 | $ | 397,443 | $ | — | $ | (78,760) | $ | 479,837 | $ | 798,568 | |||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | 13,816 | — | — | — | 13,816 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for acquisitions | — | — | 2,857,167 | — | — | — | 15,771 | — | — | — | 15,771 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exchange of Class B common stock for Class A common stock | — | — | 20,663,277 | 2 | (20,663,277) | (2) | 33,083 | — | — | (33,083) | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ESPP Issuance | — | — | 1,392,372 | — | — | — | 9,707 | — | — | — | 9,707 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impact of transactions affecting non-controlling interests | — | — | — | — | — | (5,558) | — | — | 5,558 | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | 660 | (745) | (85) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BALANCE—March 31, 2022 | — | $ | — | 205,026,367 | $ | 20 | 276,722,704 | $ | 28 | $ | 464,262 | $ | — | $ | (78,100) | $ | 451,567 | $ | 837,777 |
(in thousands, except shares) | Members' Capital | Class A Shares | Class B Shares | Additional Paid-in Capital | Notes Receivable | Accumulated Deficit | Non-Controlling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2020 | 306,843,662 | $ | 31 | — | $ | — | — | $ | — | $ | 157,560 | $ | (134) | $ | (107,832) | $ | — | $ | 49,625 | |||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | 71 | — | — | — | 71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes receivable - related parties | — | — | — | — | — | — | — | (1) | — | — | (1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | (16,114) | — | (16,114) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BALANCE—March 31, 2021 | 306,843,662 | $ | 31 | — | $ | — | — | $ | — | $ | 157,631 | $ | (135) | $ | (123,946) | $ | — | $ | 33,581 |
Three Months Ended March 31, | ||||||||||||||
(in thousands) | 2022 | 2021 | ||||||||||||
Cash Flows from Operating Activities: | ||||||||||||||
Net loss | $ | (85) | $ | (16,114) | ||||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||
Depreciation and amortization expense | 19,036 | 5,846 | ||||||||||||
Change in fair value of contingent consideration | (4,661) | 285 | ||||||||||||
Change in fair value of warrant liabilities | (27,162) | — | ||||||||||||
Loss on extinguishment of debt | 1,428 | — | ||||||||||||
Amortization of debt issuance costs | 748 | 2,170 | ||||||||||||
Non-cash lease expense | 1,705 | — | ||||||||||||
Stock-based compensation | 13,816 | 71 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||
Accounts receivable, net | (58,291) | (6,929) | ||||||||||||
Other assets | (3,060) | (882) | ||||||||||||
Prepaid expenses and other current assets | 1,773 | (6,537) | ||||||||||||
Interest accrued due to sellers | 97 | 536 | ||||||||||||
Accounts payable and accrued expenses (Related parties comprised $0 and $421 for the years ended March 31, 2022 and 2021, respectively) | 10,010 | 5,973 | ||||||||||||
Other liabilities (Related parties comprised $0 and $1,073 for the years ended March 31, 2022 and 2021, respectively) | 7,443 | 893 | ||||||||||||
Net cash used in operating activities | (37,203) | (14,688) | ||||||||||||
Cash Flows from Investing Activities: | ||||||||||||||
Purchase of property and equipment (Related parties comprised $1,677 and $1,073 for the years ended March 31, 2022 and 2021, respectively) | (7,776) | (2,645) | ||||||||||||
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired | (3,495) | (898) | ||||||||||||
Payments to sellers | (2,186) | (6,155) | ||||||||||||
Other | — | (1) | ||||||||||||
Net cash used in investing activities | (13,457) | (9,699) | ||||||||||||
Cash Flows from Financing Activities: | ||||||||||||||
Capitalized transaction costs related to merger | — | (2,414) | ||||||||||||
Payments of long-term debt | (1,611) | (1,200) | ||||||||||||
Debt issuance costs | (87) | — | ||||||||||||
Proceeds from insurance financing arrangements | 2,529 | 1,702 | ||||||||||||
Payments of principal on insurance financing arrangements | (690) | (567) | ||||||||||||
Repayments of equipment loans | (129) | (76) | ||||||||||||
Repayments of capital lease obligations | (340) | (263) | ||||||||||||
Employee stock purchase plan contributions | 870 | — | ||||||||||||
Net cash provided by (used in) financing activities | 542 | (2,818) | ||||||||||||
Net decrease in cash, cash equivalents and restricted cash | (50,118) | (27,205) | ||||||||||||
Cash, cash equivalents and restricted cash at beginning of year | 163,170 | 33,807 | ||||||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 113,052 | $ | 6,602 | ||||||||||
Supplemental cash flow information: | ||||||||||||||
Interest paid | 4,525 | 8,260 | ||||||||||||
Income taxes paid | 8 | — | ||||||||||||
Non-cash investing and financing activities: | ||||||||||||||
Right-of-use assets obtained in exchange of lease liabilities | 26,364 | 651 | ||||||||||||
Issuance of class A common stock for acquisitions | 15,771 | — | ||||||||||||
Due to sellers in connection with acquisitions | 100 | — | ||||||||||||
Addition to construction in process funded through accounts payable | 2,972 | — | ||||||||||||
Humana Affiliate Provider clinic leasehold improvements | 2,173 | 1,073 | ||||||||||||
ESPP issuance | 9,707 | — | ||||||||||||
2022 | 2021 | |||||||||||||||||||||||||
(in thousands) | Revenue $ | Revenue % | Revenue $ | Revenue % | ||||||||||||||||||||||
Capitated revenue | ||||||||||||||||||||||||||
Medicare | $ | 615,217 | 87.3 | % | $ | 220,178 | 80.2 | % | ||||||||||||||||||
Other capitated revenue | 59,134 | 8.4 | % | 41,179 | 15.0 | % | ||||||||||||||||||||
Total capitated revenue | 674,351 | 95.7 | % | 261,357 | 95.2 | % | ||||||||||||||||||||
Fee-for-service and other revenue | ||||||||||||||||||||||||||
Fee-for-service | 9,970 | 1.4 | % | 4,548 | 1.7 | % | ||||||||||||||||||||
Pharmacy | 11,515 | 1.6 | % | 7,306 | 2.7 | % | ||||||||||||||||||||
Other | 8,501 | 1.3 | % | 1,391 | 0.4 | % | ||||||||||||||||||||
Total fee-for-service and other revenue | 29,986 | 4.3 | % | 13,245 | 4.8 | % | ||||||||||||||||||||
Total revenue | $ | 704,337 | 100.0 | % | $ | 274,602 | 100.0 | % | ||||||||||||||||||
As of | ||||||||||||||
(in thousands) | March 31, 2022 | December 31, 2021 | ||||||||||||
Accounts receivable | $ | 280,461 | $ | 227,889 | ||||||||||
Medicare risk adjustment | 68,592 | 21,072 | ||||||||||||
Unpaid service provider costs | (157,329) | (115,528) | ||||||||||||
Accounts receivable, net | $ | 191,724 | $ | 133,433 |
For the three months ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Revenues | 65.1% | 73.0% |
As of | |||||||||||
March 31, 2022 | December 31, 2021 | ||||||||||
Accounts receivable | 48.8% | 43.3% |
(in thousands) | 2022 | 2021 | ||||||||||||
Balance as of January 1, | $ | 129,110 | $ | 54,524 | ||||||||||
Incurred related to: | ||||||||||||||
Current year | 401,771 | 136,755 | ||||||||||||
Prior years | 3,326 | (4,785) | ||||||||||||
405,097 | 131,970 | |||||||||||||
Paid related to: | ||||||||||||||
Current year | 207,279 | 98,761 | ||||||||||||
Prior years | 104,785 | 49,739 | ||||||||||||
312,064 | 148,500 | |||||||||||||
Balance as of March 31, | $ | 222,142 | $ | 37,994 |
(in thousands) | Weighted-Average Amortization Period | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||
Intangibles: | |||||||||||||||||||||||
Trade names | 9.00 years | $ | 1,409 | $ | (826) | $ | 583 | ||||||||||||||||
Brand | 19.26 years | 183,253 | (11,781) | 171,472 | |||||||||||||||||||
Non-compete | 4.90 years | 76,271 | (15,917) | 60,354 | |||||||||||||||||||
Customer relationships | 18.24 years | 880 | (196) | 684 | |||||||||||||||||||
Payor relationships | 20.00 years | 609,417 | (40,331) | 569,086 | |||||||||||||||||||
Provider relationships | 5.12 years | 12,242 | (3,372) | 8,870 | |||||||||||||||||||
Total intangibles, net | $ | 883,472 | $ | (72,423) | $ | 811,049 |
(in thousands) | Weighted-Average Amortization Period | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||
Intangibles: | |||||||||||||||||||||||
Trade names | 9.00 years | $ | 1,409 | $ | (787) | $ | 622 | ||||||||||||||||
Brand | 19.26 years | 183,238 | (9,037) | 174,201 | |||||||||||||||||||
Non-compete | 4.92 years | 75,794 | (12,110) | 63,684 | |||||||||||||||||||
Customer relationships | 18.24 years | 880 | (184) | 696 | |||||||||||||||||||
Payor relationships | 20.00 years | 609,362 | (32,714) | 576,648 | |||||||||||||||||||
Provider relationships | 5.12 years | 12,242 | (2,472) | 9,770 | |||||||||||||||||||
Total intangibles, net | $ | 882,925 | $ | (57,304) | $ | 825,621 |
Amount (in thousands) | ||||||||
2022 - remaining | $ | 44,543 | ||||||
2023 | 57,843 | |||||||
2024 | 55,712 | |||||||
2025 | 54,242 | |||||||
2026 | 47,063 | |||||||
Thereafter | 551,646 | |||||||
Total | $ | 811,049 |
Operating | Finance | Total | ||||||||||||||||||
2022 - remaining | $ | 20,133 | $ | 1,269 | $ | 21,402 | ||||||||||||||
2023 | 28,787 | 1,377 | 30,164 | |||||||||||||||||
2024 | 26,688 | 1,095 | 27,783 | |||||||||||||||||
2025 | 23,945 | 661 | 24,606 | |||||||||||||||||
2026 | 21,705 | 188 | 21,893 | |||||||||||||||||
Thereafter | 82,998 | 5 | 83,003 | |||||||||||||||||
Total minimum lease payments | 204,256 | 4,595 | 208,851 | |||||||||||||||||
Less: amount representing interest | (44,396) | (409) | (44,806) | |||||||||||||||||
Lease liabilities | $ | 159,860 | $ | 4,186 | $ | 164,045 | ||||||||||||||
Operating | Capital | Total | ||||||||||||||||||
2022 | $ | 23,051 | $ | 1,485 | $ | 24,536 | ||||||||||||||
2023 | 24,577 | 1,078 | 25,655 | |||||||||||||||||
2024 | 22,561 | 797 | 23,358 | |||||||||||||||||
2025 | 20,489 | 364 | 20,853 | |||||||||||||||||
2026 | 18,424 | 107 | 18,531 | |||||||||||||||||
Thereafter | 67,569 | — | 67,569 | |||||||||||||||||
Total minimum lease payments | 176,671 | 3,831 | 180,502 | |||||||||||||||||
Less: amount representing interest | (38,461) | (355) | (38,815) | |||||||||||||||||
Lease liabilities | $ | 138,210 | $ | 3,476 | $ | 141,687 | ||||||||||||||
(in thousands) | March 31, 2022 | December 31, 2021 | ||||||||||||
Service fund liability | $ | 16,547 | $ | 11,451 | ||||||||||
Acquired provider payments liability | 10,255 | 10,255 | ||||||||||||
Employee Stock Purchase Plan withholding liability | 870 | 10,494 | ||||||||||||
Other | 6,800 | 4,464 | ||||||||||||
$ | 34,472 | $ | 36,664 |
(in thousands) | Deferred revenue | |||||||
Balance at December 31, 2021 | $ | 6,059 | ||||||
Increases due to amounts collected | 2,750 | |||||||
Revenues recognized from current period increases | (620) | |||||||
Balance at March 31, 2022 | $ | 8,189 | ||||||
Years ended December 31, | Amount (in thousands) | |||||||
2022 - remaining | $ | 1,966 | ||||||
2023 | 2,628 | |||||||
2024 | 2,442 | |||||||
2025 | 1,112 | |||||||
2026 | 41 | |||||||
Total | $ | 8,189 |
(in thousands) | 2022 | 2021 | ||||||||||||
Term loan | $ | 642,822 | $ | 644,432 | ||||||||||
Senior Notes | 300,000 | 300,000 | ||||||||||||
Less: Current portion of notes payable | (6,444) | (6,493) | ||||||||||||
936,378 | 937,939 | |||||||||||||
Less: debt issuance costs | (20,640) | (22,673) | ||||||||||||
Notes payable, net of current portion and debt issuance costs | $ | 915,738 | $ | 915,266 |
(in thousands) | ||||||||
Year ending December 31, | Amount | |||||||
2022 - remainder | $ | 4,833 | ||||||
2023 | 6,444 | |||||||
2024 | 6,444 | |||||||
2025 | 6,444 | |||||||
2026 | 6,444 | |||||||
Thereafter | 912,213 | |||||||
Total | $ | 942,822 |
As of | ||||||||||||||
Unobservable Input | March 31, 2022 | December 31, 2021 | ||||||||||||
Exercise price | $11.50 | $11.50 | ||||||||||||
Stock price | $6.35 | $8.91 | ||||||||||||
Term (years) | 4.2 | 4.4 | ||||||||||||
Risk free interest rate | 2.4% | 1.2% | ||||||||||||
Dividend yield | None | None | ||||||||||||
Public warrant price | $1.58 | $2.39 |
(in thousands) | Carrying Value | Quoted Prices in Active Markets for Identical Items (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
Liabilities measured at fair value on a recurring basis: | ||||||||||||||||||||||||||
Contingent consideration | $ | 33,762 | $ | — | $ | — | $ | 33,762 | ||||||||||||||||||
Public Warrant Liabilities | 36,340 | 36,340 | — | — | ||||||||||||||||||||||
Private Placement Warrant Liabilities | 16,642 | — | — | 16,642 | ||||||||||||||||||||||
Total liabilities measured at fair value | $ | 86,744 | $ | 36,340 | $ | — | $ | 50,404 |
(in thousands) | Carrying Value | Quoted Prices in Active Markets for Identical Items (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
Liabilities measured at fair value on a recurring basis: | ||||||||||||||||||||||||||
Contingent consideration | $ | 38,423 | $ | — | $ | — | $ | 38,423 | ||||||||||||||||||
Public Warrant Liabilities | 54,970 | 54,970 | — | — | ||||||||||||||||||||||
Private Placement Warrant Liabilities | 25,174 | — | — | 25,174 | ||||||||||||||||||||||
Total liabilities measured at fair value | $ | 118,567 | $ | 54,970 | $ | — | $ | 63,597 |
(in thousands) | Balance at December 31, 2021 | Realized Gains | Balance at March 31, 2022 | |||||||||||||||||
Liabilities measured at fair value on a recurring basis: | ||||||||||||||||||||
Contingent consideration | $ | 38,423 | $ | (4,661) | $ | 33,762 | ||||||||||||||
Public and Private Placement Warrant Liabilities | 80,144 | (27,162) | 52,982 | |||||||||||||||||
Total liabilities measured at fair value | $ | 118,567 | $ | (31,823) | $ | 86,744 |
(in thousands) | Balance at December 31, 2020 | Realized Losses | Balance at March 31, 2021 | |||||||||||||||||
Liabilities measured at fair value on a recurring basis: | ||||||||||||||||||||
Contingent consideration | $ | 5,172 | $ | 285 | $ | 5,457 | ||||||||||||||
Total liabilities measured at fair value | $ | 5,172 | $ | 285 | $ | 5,457 |
(in thousands) | March 31, 2022 | December 31, 2021 | ||||||||||||
Total Assets | $ | 100,713 | $ | 80,445 | ||||||||||
Total Liabilities | $ | 75,920 | $ | 59,988 |
Three Months Ended March 31, | |||||||||||
(in thousands) | 2022 | 2021 | |||||||||
Total revenue | $ | 14,318 | $ | 991 | |||||||
Operating expenses: | |||||||||||
Third-party medical costs | 6,631 | — | |||||||||
Direct patient expense | 5,764 | 1,205 | |||||||||
Selling, general and administrative expenses | 11,639 | 2,313 | |||||||||
Depreciation and amortization expense | 814 | 247 | |||||||||
Total operating expenses | 24,848 | 3,765 | |||||||||
Net loss | $ | (10,530) | $ | (2,774) | |||||||
As of March 15, 2022 | ||||||||
Strike price | $ | 6.03 | ||||||
Risk-free interest rate | 2.1% | |||||||
Expected volatility | 70.0% | |||||||
Expected dividend yield | 0.0% | |||||||
Expected term | 6.25 |
Market-Based Stock Options | Service-Based Stock Options | |||||||||||||||||||||||||
Shares | Weighted Average Grant Date Fair Value | Shares | Weighted Average Grant Date Fair Value | |||||||||||||||||||||||
Balance, December 31, 2021 | 12,703,698 | $ | 4.23 | — | $ | — | ||||||||||||||||||||
Granted | — | — | 435,141 | 3.88 | ||||||||||||||||||||||
Vested | — | — | — | — | ||||||||||||||||||||||
Forfeitures | (5,714) | 4.23 | — | — | ||||||||||||||||||||||
Balance, March 31, 2022 | 12,697,984 | $ | 4.23 | 435,141 | $ | 3.88 |
Restricted-Stock Units | Performance - Restricted-Stock Units | |||||||||||||||||||||||||
Shares | Weighted Average Grant Date Fair Value | Shares | Weighted Average Grant Date Fair Value | |||||||||||||||||||||||
Balance, December 31, 2021 | 4,460,772 | $ | 14.43 | 706,750 | $ | 12.73 | ||||||||||||||||||||
Granted | 7,454,302 | 6.02 | — | — | ||||||||||||||||||||||
Vested | — | — | — | — | ||||||||||||||||||||||
Forfeitures | — | — | — | — | ||||||||||||||||||||||
Balance, March 31, 2022 | 11,915,074 | $ | 9.17 | 706,750 | $ | 12.73 |
Three Months Ended March 31, | |||||||||||
(in thousands, except shares and per share data) | 2022 | 2021 | |||||||||
Numerator: | |||||||||||
Net loss | $ | (85) | $ | (16,114) | |||||||
Less: net loss attributable to non-controlling interests | (745) | — | |||||||||
Net income attributable to Class A common stockholders | 660 | — | |||||||||
Dilutive effect of Class B common stock | (745) | ||||||||||
Net loss attributable to Class A common stockholders - Diluted | $ | (85) | N/A | ||||||||
Basic and Diluted Earnings Per Share denominator: | |||||||||||
Weighted average common stock outstanding - basic | 191,410,221 | N/A | |||||||||
Net income per share - basic | $ | 0.00 | N/A | ||||||||
Diluted Earnings Per Share: | |||||||||||
Dilutive effect of Class B common stock on weighted average common stock outstanding | 276,722,704 | ||||||||||
Weighted average common stock outstanding - diluted | 468,132,925 | N/A | |||||||||
Net loss per share - diluted | $ | 0.00 | N/A |
As of March 31, 2022 | |||||
Class B common stock | 276,722,704 | ||||
Public Warrants | 22,999,900 | ||||
Private Placement Warrants | 10,533,292 | ||||
Restricted Stock Units | 12,621,824 | ||||
Stock Options | 13,133,125 | ||||
Contingent Shares Issued in Connection with Acquisitions | 2,720,966 | ||||
ESPP Shares | 249,904 | ||||
Potential Common Stock Equivalents | 338,981,715 |
March 31, 2022 | December 31, 2021 | March 31, 2021 | |||||||||
Membership | 269,333 | 227,005 | 116,895 | ||||||||
Medical centers | 137 | 130 | 72 |
Three Months Ended March 31, | ||||||||||||||
($ in thousands) | 2022 | 2021 | ||||||||||||
Revenue: | ||||||||||||||
Capitated revenue | $ | 674,351 | $ | 261,357 | ||||||||||
Fee-for-service and other revenue | 29,986 | 13,245 | ||||||||||||
Total revenue | 704,337 | 274,602 | ||||||||||||
Operating expenses: | ||||||||||||||
Third-party medical costs | 535,779 | 195,046 | ||||||||||||
Direct patient expense | 60,677 | 34,237 | ||||||||||||
Selling, general, and administrative expenses | 96,587 | 35,009 | ||||||||||||
Depreciation and amortization expense | 19,036 | 5,846 | ||||||||||||
Transaction costs and other | 8,375 | 8,954 | ||||||||||||
Change in fair value of contingent consideration | (4,661) | 285 | ||||||||||||
Total operating expenses | 715,793 | 279,377 | ||||||||||||
Loss from operations | (11,456) | (4,775) | ||||||||||||
Other income and expense: | ||||||||||||||
Interest expense | (13,284) | (10,626) | ||||||||||||
Interest income | 1 | 1 | ||||||||||||
Loss on extinguishment of debt | (1,428) | — | ||||||||||||
Change in fair value of warrant liabilities | 27,162 | — | ||||||||||||
Total other income (expense) | 12,451 | (10,625) | ||||||||||||
Net income (loss) before income tax expense | 995 | (15,400) | ||||||||||||
Income tax expense | 1,080 | 714 | ||||||||||||
Net loss | (85) | (16,114) | ||||||||||||
Net loss attributable to non-controlling interests | (745) | — | ||||||||||||
Net income attributable to Class A common stockholders | $ | 660 | $ | — |
Three Months Ended March 31, | ||||||||||||||||||||||||||
2022 | 2021 | |||||||||||||||||||||||||
($ in thousands) | Revenue $ | Revenue % | Revenue $ | Revenue % | ||||||||||||||||||||||
Capitated revenue | ||||||||||||||||||||||||||
Medicare | $ | 615,217 | 87.3 | % | $ | 220,178 | 80.2 | % | ||||||||||||||||||
Other capitated revenue | 59,134 | 8.4 | % | 41,179 | 15.0 | % | ||||||||||||||||||||
Total capitated revenue | 674,351 | 95.7 | % | 261,357 | 95.2 | % | ||||||||||||||||||||
Fee-for-service and other revenue | ||||||||||||||||||||||||||
Fee-for-service | 9,970 | 1.4 | % | 4,548 | 1.7 | % | ||||||||||||||||||||
Pharmacy | 11,515 | 1.6 | % | 7,306 | 2.7 | % | ||||||||||||||||||||
Other | 8,501 | 1.3 | % | 1,391 | 0.4 | % | ||||||||||||||||||||
Total fee-for-service and other revenue | 29,986 | 4.3 | % | 13,245 | 4.8 | % | ||||||||||||||||||||
Total revenue | $ | 704,337 | 100.0 | % | $ | 274,602 | 100.0 | % |
Three Months Ended March 31, | ||||||||||||||||||||
2022 | 2021 | % Change | ||||||||||||||||||
Members: | ||||||||||||||||||||
Medicare Advantage | 119,105 | 75,488 | 57.8 | % | ||||||||||||||||
Medicare DCE | 41,201 | — | — | % | ||||||||||||||||
Medicaid | 67,982 | 21,801 | 211.8 | % | ||||||||||||||||
ACA | 41,045 | 19,606 | 109.3 | % | ||||||||||||||||
Total members | 269,333 | 116,895 | 130.4 | % | ||||||||||||||||
Member months: | ||||||||||||||||||||
Medicare Advantage | 354,415 | 224,830 | 57.6 | % | ||||||||||||||||
Medicare DCE | 125,089 | — | — | % | ||||||||||||||||
Medicaid | 202,197 | 62,908 | 221.4 | % | ||||||||||||||||
ACA | 121,911 | 56,037 | 117.6 | % | ||||||||||||||||
Total member months | 803,612 | 343,775 | 133.8 | % | ||||||||||||||||
Per Member Per Month ("PMPM"): | ||||||||||||||||||||
Medicare Advantage | $ | 1,249 | $ | 979 | 27.6 | % | ||||||||||||||
Medicare DCE | $ | 1,379 | $ | — | — | % | ||||||||||||||
Medicaid | $ | 257 | $ | 615 | (58.2) | % | ||||||||||||||
ACA | $ | 58 | $ | 44 | 31.8 | % | ||||||||||||||
Total PMPM | $ | 839 | $ | 760 | 10.4 | % | ||||||||||||||
Owned medical centers | 137 | 72 |
Three Months Ended March 31, | ||||||||||||||||||||||||||
($ in thousands) | 2022 | 2021 | $ Change | % Change | ||||||||||||||||||||||
Revenue: | ||||||||||||||||||||||||||
Capitated revenue | $ | 674,351 | $ | 261,357 | $ | 412,994 | 158.0 | % | ||||||||||||||||||
Fee-for-service and other revenue | 29,986 | 13,245 | 16,741 | 126.4 | % | |||||||||||||||||||||
Total revenue | $ | 704,337 | $ | 274,602 | $ | 429,735 |
Three Months Ended March 31, | ||||||||||||||||||||||||||
($ in thousands) | 2022 | 2021 | $ Change | % Change | ||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||
Third-party medical costs | $ | 535,779 | $ | 195,046 | $ | 340,733 | 174.7 | % | ||||||||||||||||||
Direct patient expense | 60,677 | 34,237 | 26,440 | 77.2 | % | |||||||||||||||||||||
Selling, general, and administrative expenses | 96,587 | 35,009 | 61,578 | 175.9 | % | |||||||||||||||||||||
Depreciation and amortization expense | 19,036 | 5,846 | 13,190 | 225.6 | % | |||||||||||||||||||||
Transaction costs and other | 8,375 | 8,954 | (579) | -6.5 | % | |||||||||||||||||||||
Change in fair value of contingent consideration | (4,661) | 285 | (4,946) | -1735.4 | % | |||||||||||||||||||||
Total operating expenses | $ | 715,793 | $ | 279,377 | $ | 436,416 |
Three Months Ended March 31, | ||||||||||||||||||||||||||
($ in thousands) | 2022 | 2021 | $ Change | % Change | ||||||||||||||||||||||
Other income and expense: | ||||||||||||||||||||||||||
Interest expense | $ | (13,284) | $ | (10,626) | $ | (2,658) | 25.0 | % | ||||||||||||||||||
Interest income | 1 | 1 | — | 0.0 | % | |||||||||||||||||||||
Loss on extinguishment of debt | (1,428) | — | (1,428) | 0.0 | % | |||||||||||||||||||||
Change in fair value of warrant liabilities | 27,162 | — | 27,162 | 0.0 | % | |||||||||||||||||||||
Total other income (expense) | $ | 12,451 | $ | (10,625) | $ | 23,076 | ||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||
($ in thousands) | 2022 | 2021 | ||||||||||||
Net cash used in operating activities | $ | (37,203) | $ | (14,688) | ||||||||||
Net cash used in investing activities | (13,457) | (9,699) | ||||||||||||
Net cash provided by (used in) financing activities | 542 | (2,818) | ||||||||||||
Net decrease in cash, cash equivalents and restricted cash | (50,118) | (27,205) | ||||||||||||
Cash, cash equivalents and restricted cash at beginning of year | 163,170 | 33,807 | ||||||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 113,052 | $ | 6,602 |
Three Months Ended March 31, | ||||||||||||||
($ in thousands) | 2022 | 2021 | ||||||||||||
Net loss | $ | (85) | $ | (16,114) | ||||||||||
Interest income | (1) | (1) | ||||||||||||
Interest expense | 13,284 | 10,626 | ||||||||||||
Income tax expense | 1,080 | 714 | ||||||||||||
Depreciation and amortization expense | 19,036 | 5,846 | ||||||||||||
EBITDA | $ | 33,314 | $ | 1,071 | ||||||||||
Stock-based compensation | 13,816 | 71 | ||||||||||||
De novo losses (1) | 15,816 | 5,839 | ||||||||||||
Transaction costs (2) | 9,871 | 9,818 | ||||||||||||
Restructuring and other | 2,585 | 411 | ||||||||||||
Change in fair value of contingent consideration | (4,661) | 285 | ||||||||||||
Loss on extinguishment of debt | 1,428 | — | ||||||||||||
Change in fair value of warrant liabilities | (27,162) | — | ||||||||||||
Adjusted EBITDA | $ | 45,007 | $ | 17,495 |
Exhibit Index | ||||||||
Exhibit Number | Description | |||||||
3.1 | ||||||||
3.2 | ||||||||
3.3 | ||||||||
10.1 | Sixth Amendment to Credit Agreement, dated as of January 14, 2022, by and among Cano Health, LLC, Primary Care (ITC) Intermediate Holdings, LLC, Credit Suisse AG, Cayman Islands Branch, each of the Revolving Lenders and each of the Issuing Banks (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 14, 2022). | |||||||
10.2+ | ||||||||
10.3+ | ||||||||
31.1* | ||||||||
31.2* | ||||||||
32.1** | ||||||||
32.2** | ||||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
104* | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.) |
* | Filed herewith. | ||||
** | Furnished herewith. | ||||
+ | Indicates a management contract or any compensatory plan, contract or arrangement. |
Date | Signature | Title | ||||||||||||||||||
May 9, 2022 | By: | /s/ Dr. Marlow Hernandez | Chief Executive Officer | |||||||||||||||||
Dr. Marlow Hernandez | (Principal Executive Officer) | |||||||||||||||||||
May 9, 2022 | By: | /s/ Brian D. Koppy | Chief Financial Officer | |||||||||||||||||
Brian D. Koppy | (Principal Financial Officer) | |||||||||||||||||||
May 9, 2022 | By: | /s/ Mark Novell | Chief Accounting Officer | |||||||||||||||||
Mark Novell | (Principal Accounting Officer) | |||||||||||||||||||
1. | I have reviewed this quarterly report on Form 10-Q of Cano Health, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and |
d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
By: | /s/ Dr. Marlow Hernandez | |||||||
Dr. Marlow Hernandez Chief Executive Officer (Principal Executive Officer) |
1. | I have reviewed this quarterly report on Form 10-Q of Cano Health, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and |
d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
By: | /s/ Brian D. Koppy | |||||||
Brian D. Koppy Chief Financial Officer (Principal Financial Officer) |
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. |
By: | /s/ Dr. Marlow Hernandez | |||||||
Dr. Marlow Hernandez Chief Executive Officer (Principal Executive Officer) |
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. |
By: | /s/ Brian D. Koppy | |||||||
Brian D. Koppy Chief Financial Officer (Principal Financial Officer) |